OncBioMune Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies.
To support its planned Phase II clinical trials, which will evaluate the vaccine ProscaVax for prostate cancer, the Baton Rouge, LA-based company has contracted Theradex.
Dr. Jonathan Head, OncBioMune CEO told us he met the CRO at ASCO, was impressed, and after looking at other CROs chose to move forward with Theradex.
An oncology contract research organization (CRO), Theradex also supported OncBioMune’s Phase Ia trial of ProscaVa
The Phase II studies will be conducted at the Urology Centers of North Texas (UCNT) and Harvard University teaching hospitals.
"Both Studies will be done under our present IND with the FDA," Head added.
Clinical trial management
Theradex also recently released its proprietary clinical trial management system (CTMS) for use by existing and future clients.
According to the company – a partner of the National Cancer Institute (NCI) and all 49 NCI-designated Comprehensive Cancer Centers for 35 years – the system combines data, processes, and reports on a single platform to provide real-time analytics.
"We are in a highly evolving and heavily regulated marketplace, which can be extremely challenging for many of our clients. Our CTMS system acknowledges those challenges by integrating a user-friendly, highly competent, end-to-end user platform that increases crucial insights that our clients have never had before," said Susan Davey, vice president of technology, Theradex Oncology, in a press release.